# Development of Secondary Cancers in Pre- vs Post-ICI Eligibility Periods for Metastatic Cancers

## TL;DR

This study compares the occurrence of secondary cancers in patients with metastatic cancer before and after the availability of immune checkpoint inhibitors.

## Contribution

The study provides new insights into how the use of immune checkpoint inhibitors may influence the development of secondary cancers.

## Key findings

- The incidence of secondary cancers was analyzed in relation to ICI approval timelines.
- Findings suggest a potential association between ICI use and secondary cancer development.
- The study highlights the importance of long-term monitoring of cancer patients treated with ICIs.

## Abstract

This cohort study investigates incidence of secondary primary cancers before vs after approval of immune checkpoint inhibitors (ICIs) among patients with metastatic cancers.